Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives
Published in:

13-11-2024 | Post Traumatic Stress Disorder | Practical Issues and Updates

Emerging pharmacological agents for post-traumatic stress disorder show promise, but more evidence is needed

Author: Amy Zhuang-Yan

Published in: Drugs & Therapy Perspectives | Issue 12/2024

Login to get access

Abstract

Post-traumatic stress disorder (PTSD) is a common, debilitating condition with symptoms that cause substantial stress or functional impairment. Currently, paroxetine and sertraline are the only medications approved in the USA for the treatment of PTSD, but their efficacy is limited and there is an unmet need for new pharmacological options. Several pathophysiological pathways and processes of PTSD have been highlighted as targets for potential drug development, including brain hyper- and hypoactivity, the hypothalamic-pituitary-adrenal axis and the endocannabinoid system. The use of psychedelics in combination with psychotherapy are also being investigated for the treatment of PTSD.
Literature
1.
Norred MA, Zuschlag ZD, Hamner MB. A neuroanatomic and pathophysiologic framework for novel pharmacological approaches to the treatment of post-traumatic stress disorder. Drugs. 2024;84(2):149–64.CrossRefPubMed
2.
Schnurr PP, Hamblen JL, Wolf J, et al. The management of posttraumatic stress disorder and acute stress disorder: synopsis of the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Ann Intern Med. 2024;177(3):363–74.
3.
Yehuda R, Hoge CW, McFarlane AC, et al. Post-traumatic stress disorder. Nat Rev Dis Primers. 2015;1:1–22.CrossRef
4.
5.
6.
7.
Richards A, Inslicht S, Ruoff LM, et al. An open-label study of doxazosin extended-release for PTSD: findings and recommendations for future research on doxazosin. Focus (Am Psychiatr Publ). 2018;16(1):67–73.PubMedPubMedCentral
8.
Jong J, Wauben P, Huijbrechts I, et al. Doxazosin treatment for posttraumatic stress disorder. J Clin Psychopharmacol. 2010;30(1):84–5.CrossRefPubMed
9.
Rodgman C, Verrico CD, Holst M, et al. Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. J Clin Psychiatry. 2016;77(5):e561–5.CrossRefPubMed
10.
Reist C, Streja E, Tang CC, et al. Prazosin for treatment of post-traumatic stress disorder: a systematic review and meta-analysis. CNS Spectr. 2021;26(4):338–44.CrossRefPubMed
11.
Shiroma PR, Thuras P, Wels J, et al. A proof-of-concept study of subanesthetic intravenous ketamine combined with prolonged exposure therapy among veterans with posttraumatic stress disorder. J Clin Psychiatry. 2020;81(6):20l13406.
12.
Pradhan B, Mitrev L, Moaddell R, et al. D-serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R, S)-ketamine infusion and TIMBER psychotherapy: a pilot study. Biochim Biophys Acta Proteins Proteom. 2018;1866(7):831–9.CrossRefPubMedPubMedCentral
13.
Onder E, Tural U, Aker T. A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur Psychiatry. 2006;21(3):174–9.CrossRefPubMed
14.
Giovanna G, Damiani S, Fusar-Poli L, et al. Intranasal oxytocin as a potential therapeutic strategy in post-traumatic stress disorder: a systematic review. Psychoneuroendocrinology. 2020;115: 104605.CrossRefPubMed
15.
Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025–33.CrossRefPubMedPubMedCentral
16.
Mertens LJ, Wall MB, Roseman L, et al. Therapeutic mechanisms of psilocybin: changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. J Psychopharmacol. 2020;34(2):167–80.CrossRefPubMed
Metadata
Title
Emerging pharmacological agents for post-traumatic stress disorder show promise, but more evidence is needed
Author
Amy Zhuang-Yan
Publication date
13-11-2024
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives / Issue 12/2024
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-024-01123-3

Other articles of this Issue 12/2024

Adis Summary of Research: A retrospective real-life multicenter study on concurrent oral preventive treatments in patients with chronic migraine treated with onabotulinumtoxinA

Management of lupus nephritis in children needs special considerations, but more paediatric data are required

Correction: Sodium oxybate extended-release suspension (LUMRYZ™) in narcolepsy: a profile of its use

Acknowledgement to Referees

  • Acknowledgement to Referees

Recommend existing COVID-19 vaccines to reduce serious illness but new vaccines are needed to prevent transmission

Treating acute paediatric seizure clusters warrants considerations of comfort